申请人:Hoffmann-La Roche Inc.
公开号:US05856517A1
公开(公告)日:1999-01-05
Compounds of the formula ##STR1## wherein R.sup.1 and R.sup.1' are independently alkyl, aryl, alkenyl or alkynyl; R.sup.2 and R.sup.2' are independently hydrogen or alkyl; R.sup.4, R.sup.5, R.sup.6 and R.sup.7 each independently are ##STR2## CH.sub.2 OR.sup.10, CHO, CH.sub.2 NR.sup.11 R.sup.12, hydrogen, halogen, cyano, alkyl, hydroxy, alkoxy, aryloxy, haloalkyl, nitro, amino, acylamino, aralkyloxy, monoalkylamino, dialkylamino, alkylthio, alkylsulphinyl or alkylsulphonyl, provided that at least one of R.sup.4, R.sup.5, R.sup.6 or R.sup.7 is cyano, ##STR3## CH.sub.2 OR.sup.10, CH.sub.2 NR.sup.11 R.sup.12, or CHO ; R.sup.8 is alkyl, aralkyl or aryl; R.sup.10 is hydrogen, alkyl, aralkyl or aryl; R.sup.11 and R.sup.12 are independently hydrogen, alkyl, aryl, aralkyl or acyl; one of X and Y signifies O and the other signifies O, S, (H,OH) or (H,H); as well as pharmaceutically acceptable prodrugs or salts of acidic compounds of formula I with bases and or basic compounds of formula I with acids are antiproliferative agents useful in the treatment of cancer.
式##STR1##中的化合物,其中R.sup.1和R.sup.1'分别独立地是烷基、芳基、烯基或炔基;R.sup.2和R.sup.2'独立地是氢或烷基;R.sup.4、R.sup.5、R.sup.6和R.sup.7每个独立地是##STR2## CH.sub.2 OR.sup.10、CHO、CH.sub.2 NR.sup.11 R.sup.12、氢、卤素、氰基、烷基、羟基、烷氧基、芳氧基、卤代烷基、硝基、氨基、酰胺基、芳基氧基、单烷基氨基、双烷基氨基、烷基硫基、烷基砜基或烷基砜酰基,前提是R.sup.4、R.sup.5、R.sup.6或R.sup.7中至少有一个是氰基,##STR3## CH.sub.2 OR.sup.10、CH.sub.2 NR.sup.11 R.sup.12或CHO;R.sup.8是烷基、芳基烷基或芳基;R.sup.10是氢、烷基、芳基烷基或芳基;R.sup.11和R.sup.12独立地是氢、烷基、芳基、芳基烷基或酰基;X和Y中的一个表示O,另一个表示O、S、(H,OH)或(H,H);以及具有公认的药用价值的酸性化合物或碱性化合物的药物可接受的前药或盐的抗增殖剂在癌症治疗中有用。